Publication

2024 valuations – why the mortality assumption matters

calendar icon 27 March 2024
time icon 3 mins

Authors

Leonard Bowman

Leonard Bowman

Partner & Head of Corporate Consulting

Sachin Patel

Sachin Patel

Head of Corporate DB Endgame Strategy

Andrew Udale-Smith

Andrew Udale-Smith

Partner

For schemes with a three-yearly funding valuation in 2024, life expectancy, and in particular how this might change in the future, will be a key assumption. A lot has changed in the last three years and reflecting current views on future life expectancy could save corporates millions.

It’s clear that current views of longevity will be a significant part of discussion at 2024 funding valuations and, from a corporate perspective, this will require careful consideration.

Understanding the profile of your membership, particularly with detailed analysis, and comparing the scheme to the broader UK and other real-world considerations is a helpful starting place in informing what an appropriate assumption could be.

To read our current views, click the button below.

READ MORE

For further information or support, please get in touch

Sign up for our newsletter

We pride ourselves on being thought leaders and are constantly discussing the many issues facing and shaping up our industry. Sign up to find our current thinking on topical issues.

Opens in new window Subscribe
  • Latest industry news

  • First access to upcoming events

  • Content tailored to your interests

  • Access to exclusive content

Opens in new window Subscribe